       Document 0786
 DOCN  M9650786
 TI    Some nucleoside analogs with anti-human immunodeficiency virus activity
       inhibit replication of Epstein-Barr virus.
 DT    9605
 AU    Mar EC; Chu CK; Lin JC; Tumor Virology Laboratory, Centers for Disease
       Control and; Prevention, Atlanta, GA 30333, USA.
 SO    Antiviral Res. 1995 Sep;28(1):1-11. Unique Identifier : AIDSLINE
       MED/96105493
 AB    The effects of (+)-beta-D-dioxolane-cytosine ((+)-D-beta-DOC),
       (-)-beta-L-dioxolane-cytosine ((-)-L-beta-DOC),
       (+)-beta-D-oxathiolane-cytosine ((+)-D-beta-OTC),
       (-)-beta-L-oxathiolane-cytosine ((-)-L-beta-OTC, or 3TC),
       3'-azido-2',3'-dideoxy-5-methyl-cytidine (5-Me-AZDC), and
       3'-azido-2',3'-dideoxyuridine (AZDU) on Epstein-Barr virus (EBV) DNA
       replication in vitro were tested in P3HR-1 cells. Two anti-EBV drugs,
       3'-azido-3'-deoxythymidine (AZT) and
       9-(1,3-dihydroxy-2-propoxymethyl)guanine (DHPG, or ganciclovir), were
       used as positive controls. The inhibitory effects on EBV DNA synthesis
       were quantified by membrane filter and Southern blot hybridizations with
       an EBV-specific probe BamHI-W fragment. The 50% effective doses (ED50)
       for EBV DNA replication were 0.15, 0.83, 1.5, 8.3, 14, and 7.7 microM
       for DHPG, (-)-L-beta-DOC, (+)-D-beta-DOC, (+)-D-beta-OTC,
       (-)-L-beta-OTC, and AZT, respectively. In contrast, 5-Me-AZDC and AZDU
       were not effective at concentrations as high as 30 microM. These results
       indicated that both (-)-L-beta-DOC and (+)-D-beta-DOC were more potent
       than AZT, which has previously been shown to have anti-EBV activity.
       (-)-L-beta-DOC and (+)-D-beta-DOC have also been previously demonstrated
       to suppress the infectivity of human immunodeficiency virus type 1
       (HIV-1). Thus, (-)-L-beta-DOC represents the first nucleoside analog
       with L-configuration exhibiting significant antiviral activities against
       both EBV and HIV.
 DE    Antiviral Agents/*PHARMACOLOGY  Cell Line  DNA, Viral/ANALYSIS
       Herpesvirus 4, Human/*DRUG EFFECTS/GENETICS  Human  HIV-1/DRUG EFFECTS
       Nucleosides/*PHARMACOLOGY  Structure-Activity Relationship  Support,
       U.S. Gov't, P.H.S.  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

